Every 424B that Scienture Holdings, Inc. (SCNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SCNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCNX filings page.
Scienture Holdings, Inc. launched an at-the-market equity program to sell up to $150,000,000 of common stock, with Maxim Group LLC as sales agent under its S-3 shelf.
Sales may occur on Nasdaq or through other permitted methods at prevailing prices, and Maxim will earn a 3.0% commission. The company previously sold 15,722,759 shares for gross proceeds of approximately $15,568,236 under earlier supplements. The last reported sale price was $0.75 per share on November 6, 2025.
Shares outstanding were 40,630,815 prior to this program; the filing illustrates a hypothetical post‑offering share count of 240,630,815 if 200,000,000 shares were sold at $0.75. The company’s authorized common stock is 100,000,000 shares and it will not issue above that amount; the board has recommended increasing authorization to 2,000,000,000 shares. Net proceeds are intended for working capital and general corporate purposes, including R&D, commercialization, potential debt repayment, and possible acquisitions.
Scienture Holdings filed an amended prospectus supplement to register the offer and sale of up to $9,592,009 of common stock, from time to time through Maxim Group LLC under its at-the-market program pursuant to Form S-3.
The amendment increases the amount eligible to be sold under General Instruction I.B.6, which limits primary offerings to no more than one-third of public float while it remains below $75,000,000. The company has sold approximately $13,252,250 during the prior 12 months, leaving $9,592,009 available under the Sales Agreement.
Shares trade on Nasdaq as SCNX; the last reported price was $2.60 per share on October 23, 2025. Shares outstanding were 34,474,230 as of October 23, 2025, and the aggregate market value of non-affiliate holdings used for the I.B.6 calculation was approximately $68,601,377.
Scienture Holdings, Inc. is offering securities under a prospectus supplement that discloses the company currently relies on third-party commercial manufacturing organizations (CMOs) for all production of raw materials, finished dosage forms and packaging and does not own or plan to develop its own manufacturing facilities in the foreseeable future. The prospectus shows common share counts in several states: 126,683,845, 132,309,933, and 141,123,934. It reports stockholder's equity items including negative balances shown as ($48,823,543) and ($49,195,531) and asset or similar aggregates of $77,860,464, $83,114,613, and $91,928,717. Historical net tangible book value per share as of June 30, 2025 is shown as $(1.27). The offering contemplates equity issuance from the conversion of secured convertible promissory notes (Debentures) issued November 25, 2024, conversion of Series B Preferred Stock, and the potential exercise of 2,273,930 options at a weighted average price of $1.22 and 238,594 warrants at a weighted average price of $19.02. The prospectus incorporates the company's Annual Report for year ended December 31, 2024 and Quarterly Reports for March 31 and June 30, 2025, and lists multiple Current Reports filed in 2025.